by Irinantenaina J, Carn G, Liantsoa Randriamiarinjatovo DNA , Harimanana AN , Razanatsiorimalala S, Ralemary N, Randriarison M, Razafinjato C, Hotahiene R, Randrianarivelojosia M. Parasite 2023, 30, 32. doi: 10.1051/parasite/2023034
Summary: The authors of this manuscript conducted a randomized controlled trial to assess the efficacy and safety of artesunate + amodiaquine (ASAQ) and artemether + lumefantrine (AL) at two sites in Madagascar. 347/352 (98.5%) of the included children (6 months to 14 years old) completed the study. Crude adequate clinical and parasitological response rates were 100% (95% CI: 98.8–100%) for ASAQ and 96% (95% CI: 93.1–98.9%) for AL. There were two cases of recrudescence and three re-infections. Mild and moderate adverse events were reported in 11.9% (42/352) of patients. ASAQ and AL are safe and efficacious, and may be used to treat uncomplicated P. falciparum malaria at health facilities and at the community level, and for mass drug administration.
